home / stock / pavm / pavm quote
Last: | $2.24 |
---|---|
Change Percent: | -1.3% |
Open: | $2.34 |
Close: | $2.24 |
High: | $2.4299 |
Low: | $2.16 |
Volume: | 101,694 |
Last Trade Date Time: | 05/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.24 | $2.34 | $2.24 | $2.4299 | $2.16 | 101,694 | 05-02-2024 |
$2.31 | $2.15 | $2.31 | $2.3471 | $1.995 | 153,998 | 05-01-2024 |
$2 | $1.71 | $2 | $2.06 | $1.71 | 104,476 | 04-30-2024 |
$1.71 | $1.75 | $1.71 | $1.7985 | $1.71 | 29,912 | 04-29-2024 |
$1.72 | $1.79 | $1.72 | $1.86 | $1.71 | 30,854 | 04-26-2024 |
$1.77 | $1.85 | $1.77 | $1.91 | $1.715 | 63,436 | 04-25-2024 |
$1.85 | $1.84 | $1.85 | $1.87 | $1.84 | 18,506 | 04-24-2024 |
$1.87 | $1.8704 | $1.87 | $1.9299 | $1.83 | 27,425 | 04-23-2024 |
$1.88 | $1.86 | $1.88 | $1.9 | $1.8101 | 35,936 | 04-22-2024 |
$1.86 | $1.96 | $1.86 | $1.9996 | $1.845 | 20,487 | 04-19-2024 |
$1.95 | $2 | $1.95 | $2.01 | $1.8911 | 32,067 | 04-18-2024 |
$1.97 | $1.9 | $1.97 | $1.97 | $1.81 | 30,627 | 04-17-2024 |
$1.87 | $1.99 | $1.87 | $1.99 | $1.87 | 21,012 | 04-16-2024 |
$1.91 | $1.96 | $1.91 | $2.04 | $1.88 | 49,060 | 04-15-2024 |
$1.93 | $1.97 | $1.93 | $2.04 | $1.91 | 36,459 | 04-12-2024 |
$2 | $2.09 | $2 | $2.1 | $1.9201 | 55,036 | 04-11-2024 |
$2.07 | $2.13 | $2.07 | $2.19 | $2.04 | 24,739 | 04-10-2024 |
$2.1 | $2.15 | $2.1 | $2.26 | $2.06 | 25,698 | 04-09-2024 |
$2.18 | $2.1738 | $2.18 | $2.21 | $2.0714 | 21,525 | 04-08-2024 |
$2.2 | $2.23 | $2.2 | $2.3051 | $2.15 | 23,004 | 04-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024 PR Newswire Conference Call and Webcast at 8:30AM Eastern Time NEW YORK , May 2, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or...
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing PR Newswire EsoGuard demonstrated unprecedented early precancer de...
Parties to implement a pilot program of the Veris Cancer Care Platform NEW YORK, April 30, 2024 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("...